EP1610811A4 - PREVENTION AND TREATMENT OF CARDIAC ARRHYTHMIAS - Google Patents

PREVENTION AND TREATMENT OF CARDIAC ARRHYTHMIAS

Info

Publication number
EP1610811A4
EP1610811A4 EP03813770A EP03813770A EP1610811A4 EP 1610811 A4 EP1610811 A4 EP 1610811A4 EP 03813770 A EP03813770 A EP 03813770A EP 03813770 A EP03813770 A EP 03813770A EP 1610811 A4 EP1610811 A4 EP 1610811A4
Authority
EP
European Patent Office
Prior art keywords
prevention
treatment
cardiac arrhythmias
arrhythmias
cardiac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03813770A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1610811A2 (en
Inventor
David R Hathaway
Alain D Baron
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amylin Pharmaceuticals LLC
Original Assignee
Amylin Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals LLC filed Critical Amylin Pharmaceuticals LLC
Publication of EP1610811A2 publication Critical patent/EP1610811A2/en
Publication of EP1610811A4 publication Critical patent/EP1610811A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
EP03813770A 2002-12-17 2003-12-17 PREVENTION AND TREATMENT OF CARDIAC ARRHYTHMIAS Withdrawn EP1610811A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43450802P 2002-12-17 2002-12-17
US43488802P 2002-12-19 2002-12-19
PCT/US2003/040504 WO2004056313A2 (en) 2002-12-17 2003-12-17 Prevention and treatment of cardiac arrhythmias

Publications (2)

Publication Number Publication Date
EP1610811A2 EP1610811A2 (en) 2006-01-04
EP1610811A4 true EP1610811A4 (en) 2008-03-26

Family

ID=32685317

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03813770A Withdrawn EP1610811A4 (en) 2002-12-17 2003-12-17 PREVENTION AND TREATMENT OF CARDIAC ARRHYTHMIAS

Country Status (4)

Country Link
EP (1) EP1610811A4 (enExample)
JP (1) JP2006514035A (enExample)
AU (1) AU2003297356A1 (enExample)
WO (1) WO2004056313A2 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
EP1789440A4 (en) 2004-02-11 2008-03-12 Amylin Pharmaceuticals Inc REASONS FOR THE FAMILY OF PANCREATIC POLYPEPTIDES AND POLYPEPTIDES CONTAINING THEM
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
CA2597649A1 (en) 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Inc. Gip analog and hybrid polypeptides with selectable properties
DK1888103T3 (da) 2005-04-11 2012-04-23 Amylin Pharmaceuticals Inc Anvendelse af glp-1, exendin og agonister deraf til forsinkelse eller forhindring af kardial remodellering
EP1922336B1 (en) * 2005-08-11 2012-11-21 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
MX2008002028A (es) * 2005-08-11 2008-03-27 Amylin Pharmaceuticals Inc Polipeptidos hibridos con propiedades de seleccion.
MX2008015107A (es) * 2006-05-26 2008-12-09 Amylin Pharmaceuticals Inc Composicion y metodos para el tratamiento de insuficiecia cardiaca congestiva.
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
RU2413528C2 (ru) 2007-01-18 2011-03-10 Открытое Акционерное Общество "Валента Фармацевтика" Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения
JP2009019027A (ja) * 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
AU2008306190A1 (en) * 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Use of bubuc and optionally EAA-MART1 (26-35) as a therapeutic agent for the treatment of HCMV infections
HUE031900T2 (en) 2008-12-10 2017-08-28 Glaxosmithkline Llc Pharmaceutical compositions containing Albiglutide
EP2566502A4 (en) 2010-05-04 2013-10-09 Glaxosmithkline Llc METHODS OF TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND PROVIDING CARDIOVASCULAR PROTECTION
EP2771025A1 (en) * 2011-10-28 2014-09-03 Pharis Biotec GmbH A polypeptide for the protection against heart ischemia-reperfusion injury
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
HUE035803T2 (en) 2012-12-21 2018-05-28 Sanofi Sa Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
RU2573933C1 (ru) 2014-08-21 2016-01-27 Дафот Энтерпрайсис Лимитед Пептид для лечения сахарного диабета 2-го типа и его осложнений
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
BR112020002804A2 (pt) 2017-08-24 2020-07-28 Novo Nordisk A/S composição farmacêutica líquida, e, kit
CN108939052B (zh) * 2018-09-04 2021-03-16 江苏省中医药研究院 艾塞那肽在制备预防或治疗房颤的药物中的用途
CN110551203B (zh) * 2019-09-25 2023-02-10 成都奥达生物科技有限公司 一种艾塞那肽类似物
TW202228762A (zh) * 2020-01-30 2022-08-01 美商美國禮來大藥廠 提派肽(tirzepatide)之治療用途
IL294521A (en) 2020-02-18 2022-09-01 Novo Nordisk As glp-1 compounds and their uses

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008531A1 (en) * 1996-08-30 1998-03-05 Eli Lilly And Company Use of glp-1 or analogs in treatment of myocardial infarction
WO1999040788A1 (en) * 1998-02-13 1999-08-19 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and glp-1
WO2001087322A2 (en) * 2000-05-17 2001-11-22 Bionebraska, Inc. Peptide pharmaceutical formulations
US20020146405A1 (en) * 2000-10-20 2002-10-10 Coolidge Thomas R. Treatment of hibernating myocardium and diabetic cardiomyopathy with a GLP-1 peptide
WO2002085406A1 (en) * 2001-04-24 2002-10-31 Restoragen, Inc. Methods and compositions for treating conditions associated with insulin resistance
EP1512410A1 (en) * 1999-04-30 2005-03-09 Amylin Pharmaceuticals, Inc. Use of a composition for treating organ tissue injury caused by reperfusion of blood flow following a period of ischemia

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001263230B2 (en) * 2000-05-19 2005-03-10 Amylin Pharmaceuticals, Llc Treatment of acute coronary syndrome with glp-1

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008531A1 (en) * 1996-08-30 1998-03-05 Eli Lilly And Company Use of glp-1 or analogs in treatment of myocardial infarction
WO1999040788A1 (en) * 1998-02-13 1999-08-19 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and glp-1
EP1512410A1 (en) * 1999-04-30 2005-03-09 Amylin Pharmaceuticals, Inc. Use of a composition for treating organ tissue injury caused by reperfusion of blood flow following a period of ischemia
WO2001087322A2 (en) * 2000-05-17 2001-11-22 Bionebraska, Inc. Peptide pharmaceutical formulations
US20020146405A1 (en) * 2000-10-20 2002-10-10 Coolidge Thomas R. Treatment of hibernating myocardium and diabetic cardiomyopathy with a GLP-1 peptide
WO2002085406A1 (en) * 2001-04-24 2002-10-31 Restoragen, Inc. Methods and compositions for treating conditions associated with insulin resistance

Also Published As

Publication number Publication date
AU2003297356A1 (en) 2004-07-14
JP2006514035A (ja) 2006-04-27
WO2004056313A3 (en) 2004-11-25
EP1610811A2 (en) 2006-01-04
AU2003297356A8 (en) 2004-07-14
WO2004056313A2 (en) 2004-07-08

Similar Documents

Publication Publication Date Title
AU2003297356A8 (en) Prevention and treatment of cardiac arrhythmias
AU2003290548A8 (en) Prevention and treatment of synucleinopathic disease
IL161957A0 (en) Device and procedure to treat cardiac atrial arrhythmias
TWI347188B (en) Treatment and prevention of osteoporosis
AU8880701A (en) Cardiac arrhythmia treatment methods
IL164266A0 (en) Treatment of gastroparesis
AU2003287354A8 (en) An intracardiac catheter and method of use
AU2003268295A8 (en) "diagnosis and treatment of infertility"
GB0213869D0 (en) The treatment of pain
HUP0303306A3 (en) Use of il-18 inhibitors for the treatment and/or prevention of heart disease
AU2003233681A8 (en) Diagnosis and treatment of human dormancy syndrome
GB0211295D0 (en) Treatment of pain
GB0115707D0 (en) Treatment and prevention of lipodermatosclerosis
IL176027A0 (en) Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure
IL179560A0 (en) Novel oxabispidine compounds and their use in the treatment of cardiac arrhythmias
AU2003231279A8 (en) Prevention and treatment of type 2 diabetes
GB0101146D0 (en) Treatment of skin conditions
AU2003213898A1 (en) Prevention and treatment of mycoplasma-associated diseases
EP1560592A4 (en) TREATMENT OF ALLGIELES
IL153485A0 (en) New bispidine compounds and their use in the treatment of cardiac arrhythmias
AU2003207315A1 (en) Treatment of muscle damage
ZA200610297B (en) Novel oxabispidine compounds and their use in the treatment of cardiac arrhythmias
GB0316940D0 (en) Treatment of skin and other medical conditions
IL153452A0 (en) Treatment and prevention of cardiac insulin resistance associated conditions
AU2003235665A8 (en) Diagnostic and therapeutic uses of topors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050707

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

A4 Supplementary search report drawn up and despatched

Effective date: 20080214

RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20080220

17Q First examination report despatched

Effective date: 20080519

R17C First examination report despatched (corrected)

Effective date: 20080610

APBK Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNE

APBN Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2E

APBR Date of receipt of statement of grounds of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA3E

APAF Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNE

APBT Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9E

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120703

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/575 20060101ALI20140815BHEP

Ipc: A61P 9/06 20060101ALN20140815BHEP

Ipc: A61K 38/22 20060101AFI20140815BHEP